FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285388711> ?p ?o ?g. }

• W4285388711 endingPage "4353" @default.
• W4285388711 startingPage "4346" @default.
• W4285388711 abstract "Abstract Purpose: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental Design: Up to four cycles of radioligand therapy (RLT) were offered to patients with (i) progressive metastatic malignancy, (ii) exhaustion of approved therapies, and (iii) high fibroblast activation protein (FAP) expression, defined as SUVmax ≥ 10 in more than 50% of tumor. Primary endpoint was RECIST response after RLT. Secondary endpoints included PET response (PERCIST), overall survival (OS), dosimetry, and safety of FAP-RLT. Results: Among 119 screened patients, 21 (18%) were found eligible [n = 16/3/1/1 sarcoma/pancreatic cancer/prostate/gastric cancer; 38% Eastern Cooperative Oncology Group (ECOG) ≥ 2] and received 47 90Y-FAPI-46-RLT cycles; 16 of 21 (76%) patients underwent repeat RLT. By RECIST, disease control was confirmed in 8 of 21 patients [38%; 8/16 (50%) of evaluable patients). There was one partial response (PR) and seven stable diseases after RLT. Disease control was associated with prolonged OS (P = 0.013). PERCIST response was noted in 8 of 21 patients [38%; 8/15 (53%) of evaluable patients]. Dosimetry was acquired in 19 (90%) patients. Mean absorbed dose was 0.53 Gy/GBq in kidney, 0.04 Gy/GBq in bone marrow, and &lt;0.14 Gy/GBq in liver and lung. Treatment-related grade 3 or 4 adverse events were observed in 8 (38%) patients with thrombocytopenia (n = 6) and anemia (n = 6) being most prevalent. Conclusions: 90Y-FAPI-46-RLT was safe and led to RECIST PR in one case as well as stable disease in about one third of patients with initially progressive sarcomas, pancreatic cancer, and other cancers. Discontinuation after the first cycle and a low rate of PR requires future improvement of FAP-RLT." @default.
• W4285388711 created "2022-07-14" @default.
• W4285388711 creator A5006830341 @default.
• W4285388711 creator A5019916450 @default.
• W4285388711 creator A5020993128 @default.
• W4285388711 creator A5025224947 @default.
• W4285388711 creator A5031540987 @default.
• W4285388711 creator A5036507802 @default.
• W4285388711 creator A5039736409 @default.
• W4285388711 creator A5044831522 @default.
• W4285388711 creator A5053552921 @default.
• W4285388711 creator A5053681162 @default.
• W4285388711 creator A5058269910 @default.
• W4285388711 creator A5059993837 @default.
• W4285388711 creator A5062907808 @default.
• W4285388711 creator A5065239123 @default.
• W4285388711 creator A5069693032 @default.
• W4285388711 creator A5071888326 @default.
• W4285388711 creator A5078401150 @default.
• W4285388711 creator A5086811739 @default.
• W4285388711 date "2022-07-14" @default.
• W4285388711 modified "2023-10-09" @default.
• W4285388711 title "Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities" @default.
• W4285388711 cites W1140456871 @default.
• W4285388711 cites W1964818072 @default.
• W4285388711 cites W1983680048 @default.
• W4285388711 cites W1984146357 @default.
• W4285388711 cites W2019607817 @default.
• W4285388711 cites W2028082129 @default.
• W4285388711 cites W2124154627 @default.
• W4285388711 cites W2154289925 @default.
• W4285388711 cites W2155263737 @default.
• W4285388711 cites W2523333323 @default.
• W4285388711 cites W2573369749 @default.
• W4285388711 cites W2609764678 @default.
• W4285388711 cites W2796437750 @default.
• W4285388711 cites W2803484462 @default.
• W4285388711 cites W2930582547 @default.
• W4285388711 cites W3006308266 @default.
• W4285388711 cites W3011559202 @default.
• W4285388711 cites W3015411213 @default.
• W4285388711 cites W3094601468 @default.
• W4285388711 cites W3130934287 @default.
• W4285388711 cites W3158239806 @default.
• W4285388711 cites W3159514541 @default.
• W4285388711 cites W3164206095 @default.
• W4285388711 cites W3173923097 @default.
• W4285388711 cites W3176208875 @default.
• W4285388711 cites W3179223837 @default.
• W4285388711 cites W3183264162 @default.
• W4285388711 cites W3187256913 @default.
• W4285388711 cites W3200022644 @default.
• W4285388711 cites W3206673809 @default.
• W4285388711 cites W4229719081 @default.
• W4285388711 cites W4253861989 @default.
• W4285388711 doi "https://doi.org/10.1158/1078-0432.ccr-22-1432" @default.
• W4285388711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35833949" @default.
• W4285388711 hasPublicationYear "2022" @default.
• W4285388711 type Work @default.
• W4285388711 citedByCount "28" @default.
• W4285388711 countsByYear W42853887112022 @default.
• W4285388711 countsByYear W42853887112023 @default.
• W4285388711 crossrefType "journal-article" @default.
• W4285388711 hasAuthorship W4285388711A5006830341 @default.
• W4285388711 hasAuthorship W4285388711A5019916450 @default.
• W4285388711 hasAuthorship W4285388711A5020993128 @default.
• W4285388711 hasAuthorship W4285388711A5025224947 @default.
• W4285388711 hasAuthorship W4285388711A5031540987 @default.
• W4285388711 hasAuthorship W4285388711A5036507802 @default.
• W4285388711 hasAuthorship W4285388711A5039736409 @default.
• W4285388711 hasAuthorship W4285388711A5044831522 @default.
• W4285388711 hasAuthorship W4285388711A5053552921 @default.
• W4285388711 hasAuthorship W4285388711A5053681162 @default.
• W4285388711 hasAuthorship W4285388711A5058269910 @default.
• W4285388711 hasAuthorship W4285388711A5059993837 @default.
• W4285388711 hasAuthorship W4285388711A5062907808 @default.
• W4285388711 hasAuthorship W4285388711A5065239123 @default.
• W4285388711 hasAuthorship W4285388711A5069693032 @default.
• W4285388711 hasAuthorship W4285388711A5071888326 @default.
• W4285388711 hasAuthorship W4285388711A5078401150 @default.
• W4285388711 hasAuthorship W4285388711A5086811739 @default.
• W4285388711 hasBestOaLocation W42853887111 @default.
• W4285388711 hasConcept C121608353 @default.
• W4285388711 hasConcept C126322002 @default.
• W4285388711 hasConcept C126894567 @default.
• W4285388711 hasConcept C142724271 @default.
• W4285388711 hasConcept C143998085 @default.
• W4285388711 hasConcept C197934379 @default.
• W4285388711 hasConcept C203092338 @default.
• W4285388711 hasConcept C2776694085 @default.
• W4285388711 hasConcept C2778256501 @default.
• W4285388711 hasConcept C2778822529 @default.
• W4285388711 hasConcept C2779984678 @default.
• W4285388711 hasConcept C2780210213 @default.
• W4285388711 hasConcept C2989005 @default.
• W4285388711 hasConcept C535046627 @default.
• W4285388711 hasConcept C71924100 @default.
• W4285388711 hasConceptScore W4285388711C121608353 @default.

• next